LNTH News and Press, Lantheus Holdings Inc. From 11/03/21

Lantheus (NASDAQ:LNTH) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.06 (+50.0% Y/Y) and the consensus Revenue Estimate is $97.13M (+9.7% Y/Y). Over the last 2 years, LNTH has beaten EPS estimates 100% of the time ...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Russell 2000 Value Index partially closed its multiye...

NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results fo...

The following slide deck was published by Lantheus Holdings, Inc. in conjunction with this event. For further details see: Lantheus Holdings (LNTH) presents at Baird 2021 Global Healthcare Conference

NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to fi...

NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostat...

The following slide deck was published by Lantheus Holdings, Inc. in conjunction with this event. For further details see: Lantheus Holdings (LNTH) Investor Presentation

Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERICA, Mass.,...

NORTH BILLERICA, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and f...

aPROMISE was developed to quantify and standardize assessment of PSMA PET/CT images and will support PYLARIFY ® (piflufolastat F 18) adoption in the U.S. Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was...